Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

Authors: Romera, Alvaro, Peredpaya, Sergiy, Shparyk, Yaroslav, Bondarenko, Igor, Mendonça Bariani, Giovanni, Abdalla, Kathia Cristina, Roca, Enrique, Franke, Fábio, Melo Cruz, Felipe, Ramesh, Anita, Ostwal, Vikas, Shah, Pradeep, Rahuman, Sajeed Abdul, Paravisini, Alexandra, Huerga, Camino, Del Campo García, Ana, Millán, Susana

Source: In The Lancet Gastroenterology & Hepatology December 2018 3(12):845-855